- The disease
- Travellers diarrhoea is an acute gastrointestinal illness most commonly caused by enterotoxigenic Escherichia coli (ETEC) and related enteric pathogens acquired during international travel. It is the most common travel-related illness, typically affecting travellers to regions with lower sanitation standards. Symptoms range from loose stools to more severe dehydrating diarrhoea and can disrupt travel significantly. No prescription preventive medicine is currently approved for routine use in most markets.
- What the asset is trying to do
- Travelan (IMM-124E) is an oral preparation derived from hyperimmune bovine colostrum, the early milk produced by cows immunised against ETEC antigens. The product is intended to deliver antibodies directly to the gut lumen to bind and neutralise targeted enteric pathogens before they can colonise the intestinal wall. This approach differs from antibiotic prophylaxis, which acts systemically and carries resistance concerns, and from oral rehydration or treatment-focused strategies that address symptoms after infection has occurred.
- What the trial is measuring, and why it matters
- The lead trial (NCT05933525) used a controlled human infection model (CHIM), in which healthy volunteers are deliberately exposed to a defined dose of ETEC in a controlled clinical setting to assess whether the product reduces rates of diarrhoea and infection. Primary and secondary endpoints in CHIM studies typically include rates of diarrhoea, stool frequency, severity scores, and pathogen shedding, though the specific endpoints for this trial should be confirmed against the registry record (per ClinicalTrials.gov NCT05933525). The CHIM design allows efficacy to be assessed in a smaller, more controlled population than a field trial.
- Efficacy benchmarks in this setting
- No prescription prophylactic agent is currently approved by the US FDA specifically for the prevention of travellers diarrhoea. Bismuth subsalicylate has demonstrated protective efficacy in historical field trials, with one placebo-controlled study reporting a protection rate of approximately 65% against travellers diarrhoea (Steffen et al, referenced in CDC Yellow Book 2024). Antibiotic prophylaxis with agents such as rifaximin has shown protective efficacy in controlled trials, with some studies reporting protection rates above 70% (per published rifaximin prescribing information and associated clinical literature). Results from early-stage or CHIM trials of Travelan are not statistically comparable to these figures given differences in study design, population, challenge strain, and endpoints.